BioMedNewsBreaks – Silo Pharma Inc. (SILO) Announces Expansion of License Agreement and Patent Portfolio
Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that it has expanded its commercial evaluation license agreement (“CELA”) with the University of Maryland Baltimore (“UMB”) for its next-generation liposomal peptide targeting autoimmune diseases. “We are delighted to expand our partnership with UMB. Pre-clinical testing of these peptides has shown positive results in animal studies. The three-phage peptides we identified specifically target inflamed vascular endothelium of arthritic joints in an adjuvant-induced arthritis rat model,” said Eric Weisblum, CEO of Silo Pharma. “To test the therapeutic effect of the peptides, arthritic…